Last-Resort drug shows promise for tough head and neck cancers
NCT ID NCT02369458
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tested the drug mitomycin C in 48 adults with incurable head and neck cancer that had stopped responding to standard therapies. The goal was to see if the drug could shrink tumors. The trial focused on two groups: patients with HPV-related and HPV-unrelated cancers. Results help determine if this older chemotherapy can offer a new option when other treatments fail.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.